Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of PCI Biotech Holding ASA was 42.80% per year. The lowest was -36.00% per year. And the median was 0.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PCI Biotech Holding ASA 3-Year EBITDA Growth Rate Related Terms
OSL:PCIB vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.80% mean?
PCI Biotech Holding ASA (OSL:PCIB) has a 3-Year EBITDA Growth Rate of 42.80% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PCI Biotech Holding ASA and its competitors. This is 4405% above median its historical median of 0.95.
Is PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate too high?
PCI Biotech Holding ASA's current 3-Year EBITDA Growth Rate of 42.80% is 4405% above median its 10-year median of 0.95. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. PCI Biotech Holding ASA's value of 42.80% is 187.2% above this industry median. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate of 42.80% can be compared against companies in the Biotechnology industry. The industry median 3-Year EBITDA Growth Rate is 14.90. PCI Biotech Holding ASA's value of 42.80% is 187.2% above this benchmark. While the company's 10-year median is 0.95 vs. the industry median of 14.90, PCI Biotech Holding ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PCI Biotech Holding ASA's current 3-Year EBITDA Growth Rate of 42.80% is 187.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current 3-Year EBITDA Growth Rate is 42.80%, which is 4405% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current 3-Year EBITDA Growth Rate of 42.80%. The current 3-Year EBITDA Growth Rate is 42.80%, which is 4405% above median its 10-year median of 0.95 and 187.2% above the Biotechnology industry median of 14.90. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current 3-Year EBITDA Growth Rate is 42.80% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
